Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $48.11 USD
Change Today -0.81 / -1.66%
Volume 1.4M
SNY On Other Exchanges
Symbol
Exchange
EN Paris
New York
OTC US
Mexico
Frankfurt
NASDAQ GM
As of 8:04 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

54, Rue La Boétie

Paris, 75008

France

Phone: 33 1 53 77 40 00

Fax: 33 1 53 77 42 96

ldren two years of age and older. Allegra is also launched on the OTC market in Japan. Allegra/Telfast is marketed in approximately 80 countries. The major country contributing to Allegra/Telfast sales was Japan in 2014. Depakine: Depakine (sodium valproate) is an anti-epileptic drug. Depakine is also a mood stabilizer, registered in various countries in the treatment of manic episodes within the scope of bipolar disorder and in the prevention of mood relapses and recurrences. The company produces a range of Depakine formulations, meeting the specific requirements of the various types of patients, such as syrup, oral solution, injection, enteric tablet, Depakine Chrono (a sustained release tablet) and Depakine Chronosphere (a granule formulation packaged in sachets, a form particularly suitable for children, the elderly and adults with difficulties swallowing). Depakine is registered in 130 countries and marketed in 124 countries. Sodium valproate generics are available in various markets. The major countries contributing to net sales of Depakine were China, the United Kingdom, and Italy in 2014. Stilnox/Ambien/Myslee: Stilnox (zolpidem tartrate) is indicated in the short-term treatment of insomnia. Stilnox rapidly induces sleep that is qualitatively close to natural sleep and devoid of certain side effects that are characteristic of the benzodiazepine class as a whole. Stilnox is marketed in approximately 100 countries. It is available under the brand name Ambien/AmbienCR in the United States and Myslee in Japan, where it is co-promoted jointly with Astellas. Stilnox and Ambien CR are subject to generic competition in various markets, including the United States and Europe. In Japan, generics of Myslee entered the market in 2012. In 2014, the main countries contributing to Stilnox/Ambien/Myslee sales were Japan and the United States. Synvisc/Synvisc-One: Synvisc and Synvisc-One (hylan G-F 20) are viscosupplements used to treat pain associated with osteoarthritis. Synvisc is indicated for the treatment of pain associated with osteoarthritis of the knee, hip, ankle, and shoulder joint in countries that have adopted CE marking, and for pain due to knee osteoarthritis in the United States. Synvisc-One is approved for use in patients with osteoarthritis of the knee in United States and countries that require CE marking. The major viscosupplementation market is for the treatment of pain associated with osteoarthritis of the knee. Synvisc is a triple-injection product and Synvisc-One a single-injection product. Both are administered directly into the intra-articular space of the joint to temporarily restore osteoarthritis synovial fluid. In 2014, the main countries contributing to Synvisc and Synvisc One sales were the United States, Mexico, France, Canada, Germany and Brazil. Multaq: Multaq (dronedarone) is the most extensively studied anti arrhythmic drug in AF and has demonstrated a cardiovascular outcome benefit in the ATHENA study in addition to effective rhythm control in the EURIDIS and ADONIS studies. Multaq is a multichannel blocker with both rhythm (prevention of AF recurrences) and rate (decrease of ventricular rate) controlling properties and additional effects (anti-hypertensive, vasodilatory). It is the first and only anti arrhythmic drug to have shown a significant reduction in cardiovascular hospitalization and death in patients with paroxysmal and persistent AF. The major countries contributing to Multaq sales were the United States, Germany, and Italy in 2014. Actonel: Actonel (risedronate sodium) is a biphosphonate used for the treatment of osteoporosis and Paget's disease. Auvi-Q: Auvi-Q (epinephrine injection, USP), is the first-and-only epinephrine auto-injector with audio and visual cues that talk you through the injection process. Auvi-Q is for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. The company licensed the North American commercialization rights to Auvi-Q from Kaleo Pharma. Auvi-Q is marketed as Allerject in Canada. CHC In 2014, the company’s product launches worldwide included the foll

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNY:US $48.11 USD -0.81

SNY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $60.50 USD -1.91
Amgen Inc $147.46 USD -4.32
Bayer AG €117.65 EUR +2.00
Gilead Sciences Inc $101.49 USD -3.58
Novo Nordisk A/S kr358.60 DKK 0.00
View Industry Companies
 

Industry Analysis

SNY

Industry Average

Valuation SNY Industry Range
Price/Earnings 24.2x
Price/Sales 3.2x
Price/Book 2.0x
Price/Cash Flow 16.0x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-ADR, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.